TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18422802

Group type: EXPERIMENTAL
Intervention: IABP-induced pulsatile CPB (Group B)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Nonpulsatile CPB with IABP discontinued (Group A)
Number of subjects: 96
Study: 22614132

Group type: EXPERIMENTAL
Intervention: ProSeal Laryngeal Mask Airway (PLMA™)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 75
Study: 15948916

Group type: EXPERIMENTAL
Intervention: Clinical drug trial
Number of subjects: 0
Study: 12645643

Group type: EXPERIMENTAL
Intervention: AGI-1067
Number of subjects: 0
Study: 9893928

Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride (AZ), administered over a 4-week period
Number of subjects: 0
Study: 7535938

Group type: EXPERIMENTAL
Intervention: Xanomeline tartrate 100 mg tid
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Xanomeline tartrate 115 mg tid
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2814916

Group type: EXPERIMENTAL
Intervention: Cyclosporine administered orally twice a day (9 a.m. and 21 p.m.)
Number of subjects: 9
Study: 791234

Group type: EXPERIMENTAL
Intervention: Promethazine 25 mg plus Ephedrine 12.5 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Scopolamine by mouth
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Scopolamine transdermally
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Promethazine 12.5 mg plus Ephedrine 25 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 29266524

Group type: EXPERIMENTAL
Intervention: Web-based cognitive rehabilitation therapy program (eReCog)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 76
Study: 28478583

Group type: EXPERIMENTAL
Intervention: 3 cm from the pylorus
Number of subjects: 60

Group type: COMPARATOR
Intervention: 8 cm from the pylorus
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 3 cm from the pylorus (diabetic patients)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 8 cm from the pylorus (diabetic patients)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 3 cm from the pylorus (non-diabetic patients)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 8 cm from the pylorus (non-diabetic patients)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 25395149

Group type: EXPERIMENTAL
Intervention: Totally Laparoscopic Distal Gastrectomy (TLDG)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Laparoscopy-Assisted Distal Gastrectomy (LADG)
Number of subjects: 110
Study: 23339314

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Waiting list condition
Number of subjects: 83
Study: 21796707

Group type: EXPERIMENTAL
Intervention: Curcumin 500 mg/day
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Curcumin 6 g/day
Number of subjects: 3

Group type: COMPARATOR
Intervention: Vitamin E 200 IU/day
Number of subjects: 3
Study: 18295497

Group type: EXPERIMENTAL
Intervention: Tiprolisant
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 16431893

Group type: EXPERIMENTAL
Intervention: ARB (Angiotensin II-receptor blockers)
Number of subjects: 56

Group type: COMPARATOR
Intervention: CCB (Calcium-channel blocker)
Number of subjects: 56
Study: 12908681

Group type: EXPERIMENTAL
Intervention: 8% sevoflurane
Number of subjects: 34

Group type: COMPARATOR
Intervention: 5% sevoflurane
Number of subjects: 34

Group type: COMPARATOR
Intervention: Propofol (2.0 mg x kg(‐1) i.v.)
Number of subjects: 34
Study: 10884325

Group type: EXPERIMENTAL
Intervention: GABA(A) receptor subtypes immunohistochemically analyzed with subunit‐specific antibodies (alpha1, alpha2, alpha3, beta2,3, and gamma2)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: GABA(A) receptor subunit staining
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: GABA(A) receptor alpha2‐subunit
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: GABA(A) receptor alpha1‐subunit
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: GABA(A) receptor beta2,3- and gamma2-subunits
Number of subjects: 16
Study: 9389113

Group type: EXPERIMENTAL
Intervention: Kexue Ning (stopping hemoptysis)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Western medicine (control)
Number of subjects: 0
Study: 1638070

Group type: EXPERIMENTAL
Intervention: Clobetasol-17-propionate applied every third day (1/2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clobetasol-17-propionate applied every fifth day (1/4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clobetasol-17-propionate applied every seventh day (1/6)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clobetasol-17-propionate applied every ninth day (1/8)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 6374098

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 30157787

Group type: EXPERIMENTAL
Intervention: Uterine artery ligation
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study: 27210276

Group type: COMPARATOR
Intervention: Medical Therapy (MT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Amniotic Membrane Transplantation (AMT) with Medical Therapy (MT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Topical Umbilical Cord Serum (UCS) with Medical Therapy (MT)
Number of subjects: 45
Study: 26250838

Group type: EXPERIMENTAL
Intervention: 5Cs consultation model training (asynchronous and live)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (baseline)
Number of subjects: 0
Study: 24016491

Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing (using clinical information plus genotype)
Number of subjects: 1022

Group type: COMPARATOR
Intervention: Clinical-guided dosing (using only clinical information)
Number of subjects: 1022
Study: 21397626

Group type: EXPERIMENTAL
Intervention: Citicoline treatment for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 18313446

Group type: EXPERIMENTAL
Intervention: Ultralow-dose transdermal estradiol (0.014 mg/day)
Number of subjects: 417

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study: 16983107

Group type: EXPERIMENTAL
Intervention: Simultaneous chemoradiotherapy (paclitaxel 60 mg/m2 weekly)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Radiotherapy alone (60 Gy)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Simultaneous chemoradiotherapy
Number of subjects: 214

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 214
Study: 16331853

Group type: EXPERIMENTAL
Intervention: Hospital-based medical day-treatment program
Number of subjects: 230

Group type: COMPARATOR
Intervention: Community-based nonmedical day treatment programs
Number of subjects: 230

Group type: COMPARATOR
Intervention: Nonmedical site with worse outcomes
Number of subjects: 230
Study: 11386894

Group type: EXPERIMENTAL
Intervention: Warfarin in clinical practice
Number of subjects: 410

Group type: COMPARATOR
Intervention: Warfarin in randomized trials
Number of subjects: 410
Study: 9041624

Group type: EXPERIMENTAL
Intervention: Cefixime (CFX; 8 mg/kg once daily)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (A/C; 40 mg/kg/day in three divided doses)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Cefixime (CFX)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (A/C)
Number of subjects: 313
Study: 8181578

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control
Number of subjects: 49
Study: 3580942

Group type: EXPERIMENTAL
Intervention: Radiochemotherapy plus MER/BCG (RCM)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Radiochemotherapy (RC)
Number of subjects: 44
Study: 29701561

Group type: EXPERIMENTAL
Intervention: G‐CSF (300 μg/day, 7 subcutaneous administrations over 1 week)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: G‐CSF
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 28087128

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (8 days/40 IU twice daily)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (8 days/10 puffs twice daily)
Number of subjects: 120
Study: 26308026

Group type: EXPERIMENTAL
Intervention: Version B (cars in parking spaces separated from the sidewalk by grass verges and trees)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Version A (cars parked partially on the sidewalk)
Number of subjects: 74
Study: 23168307

Group type: EXPERIMENTAL
Intervention: Rewards-based incentive (credits on study store gift card)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Baseline period (pre-intervention)
Number of subjects: 58
Study: 20621520

Group type: EXPERIMENTAL
Intervention: 24-hour intravenous (IV) insulin infusion (ISI) adjusted to maintain PGL within 4.5-7.0 mmol/L (81-126 mg/dL), n=26
Number of subjects: 50

Group type: COMPARATOR
Intervention: Subcutaneous insulin if PGL was >10.0 mmol/L (>180 mg/dL) (control group [CG]), n=24
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 24-hour intravenous (IV) insulin infusion (ISI)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Subcutaneous insulin if PGL was >10.0 mmol/L (>180 mg/dL) (control group [CG])
Number of subjects: 50
Study: 18308081

Group type: EXPERIMENTAL
Intervention: Transperineal biopsy
Number of subjects: 246

Group type: COMPARATOR
Intervention: Transrectal biopsy
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Transperineal and Transrectal biopsy
Number of subjects: 246
Study: 16210415

Group type: EXPERIMENTAL
Intervention: Intralipid at 1.33 kcal/min for 50 min
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intralipid at 4 kcal/min for 50 min
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intralipid at 1.33 kcal/min for 150 min
Number of subjects: 11

Group type: COMPARATOR
Intervention: Saline for 150 min
Number of subjects: 11
Study: 12963171

Group type: EXPERIMENTAL
Intervention: Continuous intrauterine system with continuous levonorgestrel release (20 microg/24 h) combined with oral estradiol (2 mg daily)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cyclic oral regimen of norethisterone acetate (1 mg on day 13‐22) and estradiol (days 1‐21; 2 mg, days 22‐28; 1 mg)
Number of subjects: 200
Study: 10342514

Group type: EXPERIMENTAL
Intervention: 20% LCT emulsion (group 1, n=6)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 20% MCT/LCT emulsion (group 2, n=6)
Number of subjects: 12
Study: 8949437

Group type: EXPERIMENTAL
Intervention: Gold sodium thiomalate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1807610

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 6784739

Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 70

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Narcotic premedication with Enflurane
Number of subjects: 70

Group type: COMPARATOR
Intervention: Narcotic premedication with Halothane
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Enflurane and Halothane
Number of subjects: 70
Study: 29221791

Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 16
Study: 28700473

Group type: EXPERIMENTAL
Intervention: Plasma NGAL
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intraoperative diuresis
Number of subjects: 48
Study: 26120981

Group type: EXPERIMENTAL
Intervention: Cytoflavin (10ml of the solution in one injection once a day in 200 ml of isotonic solution of sodium chloride intravenously in drops in the morning during 10 days)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard treatment (nonsteroid anti‐inflammatory drugs, myorelaxants, vitamins)
Number of subjects: 120
Study: 23927582

Group type: EXPERIMENTAL
Intervention: Levofloxacin (750 mg/day)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg/day)
Number of subjects: 182
Study: 20223273

Group type: EXPERIMENTAL
Intervention: Etch-rinse adhesive (Adper Scotchbond 1XT and Filtek Supreme)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Self-etch adhesive (Filtek Silorane adhesive and composite)
Number of subjects: 42
Study: 18469158

Group type: EXPERIMENTAL
Intervention: Once-weekly epoetin alfa
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control (twice- or thrice-weekly epoetin alfa)
Number of subjects: 83
Study: 17000937

Group type: EXPERIMENTAL
Intervention: Care transitions intervention
Number of subjects: 750
Study: 12677616

Group type: EXPERIMENTAL
Intervention: Single-stimulation infraclavicular brachial plexus block (ICB) with 40 mL of ropivacaine 0.75%
Number of subjects: 100

Group type: COMPARATOR
Intervention: Triple-stimulation axillary block (AxB) with 40 mL of ropivacaine 0.75%
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Single-stimulation infraclavicular brachial plexus block (ICB)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Triple-stimulation axillary block (AxB)
Number of subjects: 100
Study: 10898061

Group type: EXPERIMENTAL
Intervention: Face mask during CAPD bag exchange
Number of subjects: 64

Group type: COMPARATOR
Intervention: No face mask during CAPD bag exchange
Number of subjects: 64
Study: 8642959

Group type: COMPARATOR
Intervention: Mefloquine
Number of subjects: 5193

Group type: EXPERIMENTAL
Intervention: Artemisinin derivatives
Number of subjects: 5193

Group type: EXPERIMENTAL
Intervention: Retreatment with artemisinin derivatives
Number of subjects: 5193

Group type: EXPERIMENTAL
Intervention: Introduction of artemisinin derivatives in routine treatment
Number of subjects: 5193
Study: 1873424

Group type: EXPERIMENTAL
Intervention: Oral tilidine-naloxone
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 6313436

Group type: EXPERIMENTAL
Intervention: Hysterosalpingography with oil contrast medium
Number of subjects: 121

Group type: COMPARATOR
Intervention: Hysterosalpingography with aqueous contrast medium
Number of subjects: 121
Study: 3896353

Group type: EXPERIMENTAL
Intervention: Vincristine added to cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFPV)
Number of subjects: 427

Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP)
Number of subjects: 427
Study: 31406274

Group type: EXPERIMENTAL
Intervention: Black smokers
Number of subjects: 366

Group type: COMPARATOR
Intervention: White smokers
Number of subjects: 366
Study: 30196270

Group type: EXPERIMENTAL
Intervention: Supervised exercise and gym membership
Number of subjects: 0

Group type: COMPARATOR
Intervention: Motivational discussions and self-monitoring of PA using fitness trackers
Number of subjects: 0
Study: 26377522

Group type: EXPERIMENTAL
Intervention: Stigmatizing images and text in antiobesity advertisements
Number of subjects: 161

Group type: COMPARATOR
Intervention: Nonstigmatizing images and text in antiobesity advertisements
Number of subjects: 161
Study: 24834504

Group type: EXPERIMENTAL
Intervention: SRP + MTZ (400 mg TID)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: SRP + MTZ + AMX (500 mg TID)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: SRP + CHX (0.12% BID)
Number of subjects: 118

Group type: COMPARATOR
Intervention: SRP only
Number of subjects: 118
Study: 23244539

Group type: EXPERIMENTAL
Intervention: Inulin-enriched pasta
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control pasta
Number of subjects: 20
Study: 20637766

Group type: EXPERIMENTAL
Intervention: Two doses of an Adult formulation (Group HAB_2D: 150; 0‐6 months)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Three doses of a Paediatric formulation (Group HAB_3D: 150; 0‐1‐6 months)
Number of subjects: 300
Study: 18337175

Group type: EXPERIMENTAL
Intervention: Immuno-potentiating reconstituted influenza virosomes (IRIV) with synthetic malaria peptides
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pre-existing IRIV specific cellular immunity
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pre-existing influenza specific T cell responses
Number of subjects: 16
Study: 15734255

Group type: EXPERIMENTAL
Intervention: Microendoscopic discectomy (MED)
Number of subjects: 22
Study: 12869356

Group type: EXPERIMENTAL
Intervention: B9340 at 4.5 nmol/min
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: B9340 at 13.5 nmol/min
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: B9340 (13.5 nmol/min) with bradykinin (100 pmol/min)
Number of subjects: 8
Study: 10329034

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (400 mg/m2 carboplatin, and 30 mg bleomycin)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Standardized external pelvic radiation therapy
Number of subjects: 76

Group type: COMPARATOR
Intervention: No further treatment (observation)
Number of subjects: 76
Study: 8720288

Group type: EXPERIMENTAL
Intervention: Ribavirin (800 mg daily) and interferon alfa (3 MU thrice weekly) for 6 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Interferon alfa alone (3 MU thrice weekly) for 6 months
Number of subjects: 30
Study: 2025075

Group type: EXPERIMENTAL
Intervention: IMA graft
Number of subjects: 1150

Group type: COMPARATOR
Intervention: SVG graft
Number of subjects: 1150
Study: 7321036

Group type: EXPERIMENTAL
Intervention: Hand exerciser with electronic counter and visual display
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Visual display of exercises completed
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Exercise regimen
Number of subjects: 12
Study: 30862999

Group type: COMPARATOR
Intervention: Meal replacement group (MR-G) with soy-yogurt-honey preparation
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Guided lifestyle change group (LC-G) with endurance activity and nutrition counselling
Number of subjects: 26
Study: 30113670

Group type: EXPERIMENTAL
Intervention: RNase III cleavage
Number of subjects: 0
Study: 26775079

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon (PCB) angioplasty
Number of subjects: 220

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 220
Study: 24490645

Group type: EXPERIMENTAL
Intervention: Seeing another donor treated for vasovagal symptoms
Number of subjects: 1209
Study: 21296862

Group type: EXPERIMENTAL
Intervention: rhG-CSF (10 µg/kg/day intravenous infusion once daily for 5 days)
Number of subjects: 40
Study: 19774396

Group type: EXPERIMENTAL
Intervention: Modified LRP technique
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard LRP technique
Number of subjects: 104
Study: 17395566

Group type: EXPERIMENTAL
Intervention: Systematic health education program (three sessions)
Number of subjects: 455

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 455
Study: 16392976

Group type: EXPERIMENTAL
Intervention: Case management
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Voucher for free methadone maintenance treatment (MMT)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Case management plus voucher
Number of subjects: 126

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 126
Study: 11179985

Group type: EXPERIMENTAL
Intervention: Omeprazole alone
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (H. pylori-negative GERD patients)
Number of subjects: 33
Study: 9290166

Group type: EXPERIMENTAL
Intervention: Patients treated for cryptorchidism
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (healthy men)
Number of subjects: 47
Study: 8496765

Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Codeine
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 3440773

Group type: EXPERIMENTAL
Intervention: Zinc gluconate lozenges (23 mg)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Zinc gluconate lozenges
Number of subjects: 69

Group type: COMPARATOR
Intervention: Matched placebo lozenges
Number of subjects: 69
Study: 31429599

Group type: COMPARATOR
Intervention: Resveratrol (RV) 330 mg, 3 times a day for 3 days plus an additional 330 mg on the morning of the fourth day.
Number of subjects: 10
Study: 31203517

Group type: EXPERIMENTAL
Intervention: Luspatercept
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sotatercept
Number of subjects: 0
Study: 28946576

Group type: EXPERIMENTAL
Intervention: Mat Pilates
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Reformer Pilates
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (breathing and relaxation exercises)
Number of subjects: 38
Study: 26119811

Group type: EXPERIMENTAL
Intervention: HENSD (2.5 MJ)
Number of subjects: 23

Group type: COMPARATOR
Intervention: PLACEBO (0.4 MJ)
Number of subjects: 23
Study: 23784266

Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg coadministered with quinidine 300 mg (n = 42)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg coadministered with verapamil 240 mg (n = 34)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg coadministered with dronedarone 400 mg (n = 34)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg coadministered with amiodarone 400 mg (n = 30)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg coadministered with digoxin 0.25 mg (n = 48)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg coadministered with atorvastatin 80 mg (n = 32)
Number of subjects: 220
Study: 21762407

Group type: EXPERIMENTAL
Intervention: Periodontal treatment in periodontitis patients
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Tongue cleaning in periodontitis patients
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Gingivitis treatment in gingivitis patients
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Tongue cleaning in gingivitis patients
Number of subjects: 218
Study: 19356912

Group type: EXPERIMENTAL
Intervention: 150 g cod 5 times a week
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: 150 g cod 3 times a week
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (no seafood)
Number of subjects: 126
Study: 16797729

Group type: EXPERIMENTAL
Intervention: Tonsillectomy and/or adenoidectomy (T&A)
Number of subjects: 101